IMMURON LTD-SPON ADR (IMRN) Stock News
NASDAQ:IMRN - Nasdaq - US45254U1016 - ADR - Currency: USD
IMRN Latest News, Press Relases and Analysis
Immuron Travelan® continued strong sales growth
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp...
Immuron Travelan® continued strong sales growth
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum...
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance
Immuron Announces Travelan® Clinical Trial Update
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant...
Immuron Announces Travelan® Clinical Trial Update
UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
Immuron Travelan® continued strong sales growth
Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior...
Immuron Travelan® continued strong sales growth
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated...
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile...
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor...
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
Immuron announces record Travelan® sales globally, Australia and USA
Immuron requests pre-IND meeting for IMM-529 with FDA filing
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron requests pre-IND meeting for IMM-529 with FDA filing
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
Immuron CEO Steven Lydeamore to present at Peak Sky High
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...